Cargando…
Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy
BACKGROUND: Although patients with moderate intellectual disability (ID) are known to have higher rates of being overweight and obese than those without ID, there are no current data regarding the relationship between ID and weight gain in epilepsy patients treated with valproic acid (VPA). PATIENTS...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397927/ https://www.ncbi.nlm.nih.gov/pubmed/25897238 http://dx.doi.org/10.2147/NDT.S80898 |
_version_ | 1782366772014350336 |
---|---|
author | Tanamachi, Yukiko Saruwatari, Junji Noai, Madoka Kamihashi, Ryoko Soraoka, Hiromi Yoshimori, Yuki Ogusu, Naoki Oniki, Kentaro Yasui-Furukori, Norio Ishitsu, Takateru Nakagawa, Kazuko |
author_facet | Tanamachi, Yukiko Saruwatari, Junji Noai, Madoka Kamihashi, Ryoko Soraoka, Hiromi Yoshimori, Yuki Ogusu, Naoki Oniki, Kentaro Yasui-Furukori, Norio Ishitsu, Takateru Nakagawa, Kazuko |
author_sort | Tanamachi, Yukiko |
collection | PubMed |
description | BACKGROUND: Although patients with moderate intellectual disability (ID) are known to have higher rates of being overweight and obese than those without ID, there are no current data regarding the relationship between ID and weight gain in epilepsy patients treated with valproic acid (VPA). PATIENTS AND METHODS: The possible association between moderate ID and an overweight status at the time of initiation of VPA therapy (baseline) was investigated using a logistic regression analysis in 143 patients with epilepsy. Among the 119 nonoverweight patients at baseline, the longitudinal association between moderate ID and the weight status during VPA therapy was retrospectively examined using a Cox hazards regression analysis and the generalized estimating equations approach, while also paying careful attention to associations with other patient characteristics. RESULTS: The proportion of patients with moderate ID was 52.4% among the 143 study subjects. The presence of moderate ID was not associated with an overweight status at baseline (P=0.762). Among the nonoverweight patients at baseline, 16 subjects were newly diagnosed as being overweight during treatment with VPA (3.6±2.1 years). The presence of moderate ID was significantly associated with the incidence of an overweight status after starting VPA therapy (adjusted hazard ratio =6.72, P=0.007). The patient age at baseline and treatment with co-administered carbamazepine, clobazam, and zonisamide significantly influenced the degree of weight fluctuation during VPA therapy among the patients with moderate ID (P<0.001, P<0.001, P=0.002, and P=0.028, respectively), whereas only patient age at baseline affected this parameter among the patients without moderate ID (P=0.022). CONCLUSION: The present findings suggest that the weight status should be carefully monitored in VPA-treated patients with moderate ID, especially those receiving other co-administered antiepileptic drugs that facilitate weight gain, such as carbamazepine. |
format | Online Article Text |
id | pubmed-4397927 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43979272015-04-20 Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy Tanamachi, Yukiko Saruwatari, Junji Noai, Madoka Kamihashi, Ryoko Soraoka, Hiromi Yoshimori, Yuki Ogusu, Naoki Oniki, Kentaro Yasui-Furukori, Norio Ishitsu, Takateru Nakagawa, Kazuko Neuropsychiatr Dis Treat Original Research BACKGROUND: Although patients with moderate intellectual disability (ID) are known to have higher rates of being overweight and obese than those without ID, there are no current data regarding the relationship between ID and weight gain in epilepsy patients treated with valproic acid (VPA). PATIENTS AND METHODS: The possible association between moderate ID and an overweight status at the time of initiation of VPA therapy (baseline) was investigated using a logistic regression analysis in 143 patients with epilepsy. Among the 119 nonoverweight patients at baseline, the longitudinal association between moderate ID and the weight status during VPA therapy was retrospectively examined using a Cox hazards regression analysis and the generalized estimating equations approach, while also paying careful attention to associations with other patient characteristics. RESULTS: The proportion of patients with moderate ID was 52.4% among the 143 study subjects. The presence of moderate ID was not associated with an overweight status at baseline (P=0.762). Among the nonoverweight patients at baseline, 16 subjects were newly diagnosed as being overweight during treatment with VPA (3.6±2.1 years). The presence of moderate ID was significantly associated with the incidence of an overweight status after starting VPA therapy (adjusted hazard ratio =6.72, P=0.007). The patient age at baseline and treatment with co-administered carbamazepine, clobazam, and zonisamide significantly influenced the degree of weight fluctuation during VPA therapy among the patients with moderate ID (P<0.001, P<0.001, P=0.002, and P=0.028, respectively), whereas only patient age at baseline affected this parameter among the patients without moderate ID (P=0.022). CONCLUSION: The present findings suggest that the weight status should be carefully monitored in VPA-treated patients with moderate ID, especially those receiving other co-administered antiepileptic drugs that facilitate weight gain, such as carbamazepine. Dove Medical Press 2015-04-07 /pmc/articles/PMC4397927/ /pubmed/25897238 http://dx.doi.org/10.2147/NDT.S80898 Text en © 2015 Tanamachi et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Tanamachi, Yukiko Saruwatari, Junji Noai, Madoka Kamihashi, Ryoko Soraoka, Hiromi Yoshimori, Yuki Ogusu, Naoki Oniki, Kentaro Yasui-Furukori, Norio Ishitsu, Takateru Nakagawa, Kazuko Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy |
title | Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy |
title_full | Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy |
title_fullStr | Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy |
title_full_unstemmed | Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy |
title_short | Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy |
title_sort | possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397927/ https://www.ncbi.nlm.nih.gov/pubmed/25897238 http://dx.doi.org/10.2147/NDT.S80898 |
work_keys_str_mv | AT tanamachiyukiko possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy AT saruwatarijunji possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy AT noaimadoka possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy AT kamihashiryoko possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy AT soraokahiromi possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy AT yoshimoriyuki possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy AT ogusunaoki possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy AT onikikentaro possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy AT yasuifurukorinorio possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy AT ishitsutakateru possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy AT nakagawakazuko possibleassociationbetweenmoderateintellectualdisabilityandweightgaininvalproicacidtreatedpatientswithepilepsy |